Nim­bus clinch­es $125M raise via big donor-backed pri­vate fi­nanc­ing round fol­low­ing Bris­tol My­er­s' TYK2 ap­proval

More than a year af­ter rais­ing $105 mil­lion in a pri­vate fi­nanc­ing round, Nim­bus Ther­a­peu­tics is back with its next haul as it con­sid­ers its next steps, thanks to Bris­tol My­ers Squibb.

The com­pu­ta­tion­al chem­istry biotech, co-found­ed in 2009 by VC Bruce Booth, an­nounced its most re­cent fi­nanc­ing round Mon­day worth $125 mil­lion — Nim­bus’ fifth big fi­nanc­ing in the last sev­en years.

CEO Jeb Keiper tells End­points News that the fi­nanc­ing will sup­port Nim­bus’ en­tire pipeline, in­clud­ing its lead can­di­dates and pre­clin­i­cal ef­forts. At the biotech’s fore­front is its TYK2 pro­gram, which is cur­rent­ly in a Phase IIb study for pso­ri­a­sis. And ac­cord­ing to Keiper, the biotech is run­ning hot in its at­tempt to get its TYK2 drug past the reg­u­la­to­ry fin­ish line — cour­tesy of Bris­tol My­ers beat­ing them to the punch with its own TYK2 drug just last week, now brand­ed as So­tyk­tu, for pso­ri­a­sis.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN